Avedro Inc. went public on February 14, raising $70 million with its share price at, coincidentally, $14. We talk with Reza Zadno, CEO and president, about the IPO, whose process, as you might imagine, was as difficult as it looks. We’ll also talk business. Avedro, of course, is a commercial enterprise now, reporting growing sales on its Corneal Cross-linking System that can be used to treat keratoconus, a non-inflammatory eye condition that weakens and misshapes the cornea. But what does the future hold for the start-up?
Meet Our Hosts
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.